Maneka Mirchandaney's questions to Solid Biosciences (SLDB) leadership • Q1 2021
Question
Maneka Mirchandaney of Evercore ISI asked whether the company is considering additional changes to the clinical protocol to further mitigate the risk of inflammatory events, such as adjusting the immunosuppressive drug regimen, based on the experience with Patient 8.
Answer
Acting Chief Medical Officer Dr. Cathryn Clary responded that ensuring patient safety is the top priority and that the team is actively investigating the event to determine how to best modify the risk mitigation profile. She confirmed they are exploring various options, including potential changes to dosing, but could not specify details while the investigation is ongoing with internal and external experts. Any changes would require DSMB and FDA approval.